Tirabrutinib for the treatment of relapsed or refractory primary central nervous system lymphoma: Efficacy and safety from the phase II PROSPECT study Meeting Abstract
| Authors: | Nayak, L.; Grommes, C.; Kallam, A.; Peereboom, D. M.; Ambady, P.; Mendez, J. S.; Aregawi, D. G.; Sumrall, A. L.; Omuro, A. M. P.; Iwamoto, F.; Dietrich, J.; Umemura, Y.; Munker, R.; Chukwueke, U. N.; Schaff, L.; Prados, S.; Takazawa, A.; Aoi, A.; Batchelor, T. |
| Abstract Title: | Tirabrutinib for the treatment of relapsed or refractory primary central nervous system lymphoma: Efficacy and safety from the phase II PROSPECT study |
| Meeting Title: | J. Clin. Oncol. |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 16_SUPPL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-06-01 |
| Language: | English |
| ACCESSION: | WOS:001509527500001 |
| DOI: | 10.1200/JCO.2025.43.16_suppl.2019 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- 16_SUPPL -- 2019 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics